Introduction {#s1}
============

Subcortical vascular encephalopathy (VE) is a major cause of vascular cognitive impairment leading to vascular dementia (VaD) (Moorhouse and Rockwood, [@B27]; Staekenborg et al., [@B44]). White matter lesions on brain imaging combined with clinical symptoms (including cognitive impairment, gait disturbance, and various focal neurological signs as well as incontinence) are characteristic (Baezner et al., [@B4]). Patients with VE are a heterogeneous entity (Roman et al., [@B33]), consisting of patients with and without dementia, partly with an abnormal Aβ-ratio, with and without inflammation.

In contrast, AD is neuropathologically characterized by the deposition of amyloid fibrils formed by amyloid beta (Aβ) as well as by neurofibrillary tangles which are composed of hyperphosphorylated tau protein (Serrano-Pozo et al., [@B42]). Heterogeneity regarding the clinical presentation and the disease course in AD is increasingly recognized. In the framework of our surveillance studies, we described a new subtype of AD, rapidly progressive AD (rpAD) (Schmidt et al., [@B37], [@B36]). This subtype of AD can mimic the clinical course of Creutzfeldt-Jakob disease patients with a progressive cognitive decline (\>6 mini-mental test points/year), short disease duration (\<2 years, 6--8 month) as well as early focal neurological signs, such as occurrence of extrapyramidal symptoms and myoclonus. Patients with rpAD exhibit an age range between 60 and 70 years, whereas patients with classical AD are often older at disease onset (age range 70--80 years) and a disease duration of 7 years is acknowledged (Schmidt et al., [@B36]). A problem in the clinical setting arises because current diagnostic criteria (Roman et al., [@B33]; McKhann et al., [@B25]) often fail in discriminating AD and VaD leading to the diagnosis of mixed dementia. Even though both diseases exhibit the same vascular risk factors, such as atherosclerosis, diabetes mellitus, etc., AD and VaD/VE are different disease entities. Cases exhibiting a pathophysiologic overlap of AD and VaD are considered as mixed dementia (Jellinger and Attems, [@B17]). For a reliable early diagnosis and the differentiation of AD and VaD subtypes, biomarker diagnostics may be helpful to predict the disease course. At the moment, the subgroup definition to distinguish between AD and rpAD or between VE and VaD is based on clinical criteria and neuropsychological testing (Mini Mental State test), indicating a strong need for objective quantitative compared cerebrospinal fluid (CSF) biomarkers.

Until now some effort had already been undertaken to detect characteristic immune profiles or neurodegenerative marker proteins in CSF, serum or plasma from patients with AD or VaD (Andreasen et al., [@B3]; Lee et al., [@B21]; Paraskevas et al., [@B29]; Kaerst et al., [@B19]; Stoeck et al., [@B46]; Llorens et al., [@B23]; Schmitz et al., [@B40]). Even though a differential regulation of the immune system and classical AD biomarkers (tau, p-tau, Aβ42) could be observed in both diseases (Andreasen et al., [@B3]; Paraskevas et al., [@B29]; Schmitz et al., [@B40]), the reliability of accuracy of these makers discriminating AD from VaD was not comparable to other diagnostic test systems of dementia diseases, such as assays of 14-3-3, tau or misfolded protein aggregates (Cramm et al., [@B11], [@B10]; Schmitz et al., [@B38],[@B39]). Therefore, although CSF tests may be useful in the differential diagnosis of AD from VaD, lower specificity of current biomarkers and disease heterogeneity impedes absolute discrimination in the differential diagnostic context (Andreasen et al., [@B3]; Nagga et al., [@B28]; Paraskevas et al., [@B29]).

Recent studies in our group on neurodegenerative marker profiles in AD and VaD were promising (Kaerst et al., [@B19]; Hermann et al., [@B15]) and lead us to the idea of the present study to proceed investigating the discrimination of VaD/VE from AD patients by the use of CSF biomarkers. Here, two independent patient cohorts were analyzed in parallel for the levels of classical AD CSF biomarkers total tau, p-tau, Aβ42. The neuronal damage markers 14-3-3 and neuron-specific enolase (NSE) and the inflammatory markers calcium binding protein B (S-100B) and YKL-40 were also quantified in the study cohort. Additionally, in our validation cohort we included a subgroup of AD called rapidly progressive AD (rpAD) and a group of patients with cerebral small vessel disease showing no relevant cognitive deficits called VE. The diagnostic accuracy was calculated for each marker separately as well as in combination.

Materials and methods {#s2}
=====================

Samples
-------

Cohort 1 consists of patients who underwent lumbar puncture for diagnostic purposes in the Clinical Dementia Center Göttingen and were included in this study after clinical and image-based diagnose of either AD \[based on recent criteria ICD-10 definition for Alzheimer\'s disease (AD) F.00 G.30\] or VaD (based on ICD 10 definition, F01 and NINDS-AIREN criteria (Roman et al., [@B33]). Patients with possible other neurodegenerative, neuroinflammatory and neoplastic diseases as well as patients with acute or subacute cerebral ischemia were excluded. The control group was composed of patients with either clinically or pathologically defined alternative diagnosis and included cases diagnosed with psychiatric disorders (psychosis, bipolar disorder, depression, and schizophrenia), epilepsy, autoimmune diseases, meningitis, alcohol abuse disorder, headache, vertigo, pain syndromes and alternative neurologic conditions. Control cases did not present biomarker profiles indicating the presence of a neurodegenerative disease and the presence of neurodegeneration was excluded in the follow-up clinical diagnostic process.

In Cohort 2, we included cases from a separate study on rpAD and cases from a study on cerebral small vessel disease (groups VE and VaD). Exclusion criteria were the same as mentioned above.

VaD diagnosis was based on ICD 10 definition (F01) and NINDS-AIREN criteria (Roman et al., [@B33]). VE diagnosis was based on neuroimaging (presence of white matter lesions on MRI T2, Flair, or CCT) and exclusion of inflammatory CNS disease. Patients showed signs of cerebral small vessel disease on MRI or CCT and scores of \>2 points on the ARWMC scale (Wahlund et al., [@B51]). They did not match ICD-10 criteria for dementia and showed MMSE scores \>27 points. Inflammatory CNS disease had been excluded by CSF analysis. Only in this validation cohort, presence of an AD-like biomarker signature associated with amyloid pathology was excluded for the VaD group using a CSF Aβ42/40 ratio cut-off, which has been suggested for the discrimination of AD from other forms of dementia (Lewczuk et al., [@B22]). No other biomarkers are currently available for a more accurate discrimination.

Classical AD patients were diagnosed according to the Dubois criteria (Dubois et al., [@B14]). rpAD patients were selected according to clinical presentation as reported previously by the German CJD surveillance group (Schmidt et al., [@B37], [@B36]). Rapid progression was defined by a velocity of cognitive decline \>6 pts/year on the Mini Mental Status Examination scale (Schmidt et al., [@B37]): Velocity of decline was calculated using linear regression (least square method) in accordance with Villemagne et al. ([@B50]).

Since there is a lack of autopsy acceptances, a neuropathological examination was not possible. Subgroups were separated after initial research project inclusion but before consideration for this study. All tests were performed in the Neurochemistry Laboratory at the Department of Neurology, University Medical School, Göttingen (Germany). CSF was obtained by lumbar puncture and processed immediately. CSF was examined for standard parameters, such as cell count, proteins, and immunoglobulins in order to exclude neuroinflammatory disease. No patient showed elevated cell count or intrathecal IgG synthesis.

CSF tests
---------

Routine CSF analysis did not reveal any abnormalities. CSF tau levels were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer\'s instructions. Total tau was measured using INNOTEST™ hTAU Ag; (Fujirebio), tau phosphorylated at Thr181 (p-tau) was analyzed using an ELISA kit (INNOTEST™ PHOSPHO-TAU(181 P); Fujirebio). The LIAISON® NSE was used for NSE quantification. The LIAISON SANGTEC® 100 was used for S100B detection. Levels of Aβ42 were measured with an ELISA kit (INNOTEST™ AMYLOID (1-42); Fujirebio). YKL-40 was measured using the MicroVue YKL-40 EIA ELISA kit from Quidel following manufacturer\'s instructions. Protein 14-3-3 was tested by western blot as previously described (Zerr et al., [@B53]; Schmitz et al., [@B41]).

Statistical analysis
--------------------

For two group comparisons, the Mann--Whitney test was used. In multiple comparisons, the Kruskal--Wallis test was used. Dunn\'s multiple comparison was used for *post hoc* analysis. *P*-values lower than 0.05 were considered significant. Statistical analyses and calculations of Area Under the Curve (AUC) and 95% confidence intervals from Receiver Operating Characteristic (ROC) areas were carried out using GraphPad-Prism 7 software. The best cut-off for value of a single biomarker or combination of biomarkers value was estimated based on the Youden index (Youden, [@B52]). For each biomarker or combination of biomarkers sensitivity and specificity values were calculated.

Ethics
------

The present study was conducted according to the revised Declaration of Helsinki and Good Clinical Practice guidelines and has been approved by the local ethics committee in the University Medical Center, Göttingen (No. 9/6/08, 19/11/09, and 18/8/15). Written informed consent was given by all study participants or their legal next of kin.

Results {#s3}
=======

Determination of CSF biomarker profiles in patients with Alzheimer\'s disease and vascular dementia
---------------------------------------------------------------------------------------------------

In a study cohort of 50 controls, 65 AD, and 31 VaD accurately classified patients (without mixed pathology), we measured the CSF levels of total tau, p-tau, Aβ42, YKL-40, S100B, NSE, and 14-3-3 (Table [1A](#T1){ref-type="table"}). Compared to controls, AD cases presented increased tau (*p* \< 0.01), p-tau (*p* \< 0.001), YKL-40 (*p* \< 0.001), S100B (*p* \< 0.05), and decreased Aβ42 (*p* \< 0.001) levels (Figures [1A--E](#F1){ref-type="fig"}). In contrast, VaD only presented alterations on tau (*p* \< 0.05) and Aβ42 levels (*p* \< 0.01) (Figures [1A,C](#F1){ref-type="fig"}). Significant differences of total tau (*p* \< 0.01), p-tau (*p* \< 0.001) Aβ42 (*p* \< 0.01) were detected between AD and VaD cases (Figures [1A--C](#F1){ref-type="fig"}).

###### 

Demographic and CSF biomarker data from study and validation cohorts.

                                                    **Control**     **AD**                                      **VaD**
  ------------------------------------------------- --------------- ------------------------------------------- --------------------------------------------
  **(A) STUDY COHORT-COHORT 1**                                                                                 
  **Demographics**                                                                                              
  *n*                                               50              65                                          31
  Age (years)                                       70 ± 6          67 ± 11                                     70 ± 10
  Gender (f/m)                                      27/23           43/22                                       27/6
  **Biomarkers**                                                                                                
  tau (pg/mL)[^\*^](#TN1){ref-type="table-fn"}      225 ± 103       718 ± 639                                   410 ± 300
  p-tau (pg/mL)[^\*^](#TN1){ref-type="table-fn"}    44 ± 14         77 ± 40                                     48 ± 23
  Aβ42 (pg/mL)[^\*^](#TN1){ref-type="table-fn"}     777 ± 276       378 ± 178                                   535 ± 219
  YKL-40 (pg/mL)[^\*^](#TN1){ref-type="table-fn"}   254 ± 117       400 ± 181                                   324 ± 156
  NSE (ng/mL)[^\*^](#TN1){ref-type="table-fn"}      16 ± 5          15 ± 11[^§^](#TN2){ref-type="table-fn"}     13 ± 11[^§§^](#TN3){ref-type="table-fn"}
  S100B (ng/mL)[^\*^](#TN1){ref-type="table-fn"}    2.5 ± 1.4       3.2 ± 1.9[^§^](#TN2){ref-type="table-fn"}   3.1 ± 1.2[^§§^](#TN3){ref-type="table-fn"}
  14-3-3 (p--t--n) (%*p*)                           1--0--49 (2%)   8--9--48 (12%)                              4--2--25 (13%)

                                                   **AD**      **rpAD**    **VaD**     **VE**
  ------------------------------------------------ ----------- ----------- ----------- -----------
  **(B) VALIDATION COHORT-COHORT 2**                                                   
  **Demographics**                                                                     
  *n*                                              26          15          21          25
  Age (years)[^\*^](#TN1){ref-type="table-fn"}     71 ± 11     68 ± 10     74 ± 7      74 ± 6
  Gender (f/m)                                     16/10       11/4        13/8        16/9
  **Biomarkers**                                                                       
  tau (pg/mL)[^\*^](#TN1){ref-type="table-fn"}     628 ± 456   700 ± 447   300 ± 176   301 ± 249
  p-tau (pg/mL)[^\*^](#TN1){ref-type="table-fn"}   100 ± 46    104 ± 71    59 ± 35     47 ± 23
  Aβ42 (pg/mL)[^\*^](#TN1){ref-type="table-fn"}    381 ± 99    401 ± 133   674 ± 292   875 ± 206

*Mean values ± SD*,

57 and

*26 cases analyzed, p-t-n: positive, trace, negative, % p: % of positive cases*.

*Number of cases, age, and gender distribution as well CSF biomarker profile is reported*.

![Determination of AD, inflammatory and neurodegenerative biomarker proteins in the CSF of AD, VaD, and control cases. **(A--F)** CSF levels of neurodegenerative biomarkers, total tau, *p*-tau, Aβ42, YKL-40, S100B, and NSE were measured by ELISA. **(G)** Semi-quantitative analysis of 14-3-3 levels. Patients analyzed by western blot were divided into three groups according to the 14-3-3 levels, which can be negative, trace (inconclusive) and positive. A *p* \< 0.001 was considered as extremely significant (^\*\*\*^), \< 0.01 as very significant (^\*\*^), \< 0.05 as significant (^\*^), and ≥ 0.05 as not significant.](fnagi-09-00289-g0001){#F1}

NSE levels were not different regulated between groups (Figure [1F](#F1){ref-type="fig"}). The percentage of 14-3-3 positive cases was higher in AD (12%) and VaD (13%) than in controls (2%) but not significantly different between AD and VaD patients (Figure [1G](#F1){ref-type="fig"}).

Subsequently, we validated our findings for total tau, p-tau, and Aβ42 in an independent second cohort of patients (Table [1B](#T1){ref-type="table"}). The validation cohort included the rpAD subgroup and VE cases. A comparative analysis of four different patient groups (AD, rpAD, VaD, and VE) confirmed the main observations from the study cohort, since tau (*p* \< 0.05), p-tau (*p* \< 0.01), and Aβ42 (*p* \< 0.001) were differentially regulated between AD and VaD samples (Figures [2A--C](#F2){ref-type="fig"}). Additionally, it could be shown that the subgroups rpAD and VE did not show any distinctive features when compared to AD or VaD (Figures [2A--C](#F2){ref-type="fig"}).

![Determination of selected biomarker proteins in the CSF of a validation cohort of AD, rpAD, VaD, and VE cases. **(A--C)** CSF levels of total tau, p-tau, and Aβ42 were validated in a second cohort, consisting of AD, rpAD, VaD and VE patients. A *p* \< 0.001 was considered as extremely significant (^\*\*\*^), \<0.01 as very significant (^\*\*^), \<0.05 as significant (^\*^), and ≥0.05 as not significant (ns).](fnagi-09-00289-g0002){#F2}

Analysis of diagnostic accuracy of total tau, p-tau, and Aβ42 separately and in combination
-------------------------------------------------------------------------------------------

At first, we calculated the diagnostic values of the biomarker proteins (CSF total tau, p-tau, and Aβ42), which were detected to be differently regulated between AD and VaD patients. Since no differences were detected in the biomarker profile between AD and rpAD subgroups, all AD cases were used for further analysis (*n* = 41). AUC, 95% confidence interval (CI) as well as cut-off and associated sensitivity and specificity values were calculated (Table [2](#T2){ref-type="table"}). Sensitivity/specificity values showed relative poor accuracy for single biomarker measurements, tau, p-tau, and Aβ42 in the discrimination of both diseases, with AUC values ranging from 0.70 to 0.82 (Table [2](#T2){ref-type="table"}). As reported before, a combination of different biomarker proteins may improve the diagnostic value and reliability of biomarker detection (Blennow et al., [@B6]; Llorens et al., [@B24]).

###### 

CSF biomarker accuracy in the discrimination of AD from VaD cases in study and validation cohorts.

  **Biomarker outcome**            **AUC**   **95% CI**   **Cut-off**   **Sensitivity (%)**   **Specificity (%)**
  -------------------------------- --------- ------------ ------------- --------------------- ---------------------
  **STUDY COHORT-COHORT 1**                                                                   
  AD: *n* = 65, VaD: *n* = 31                                                                 
  p-tau                            0.80      0.70--0.90   \<51          77                    81
  Aβ42                             0.70      0.59--0.81   \>412         65                    66
  Aβ42/tau                         0.79      0.69--0.88   \>1           74                    72
  Aβ42/p-tau                       0.84      0.75--0.93   \>8.2         81                    80
  tau × p-tau/Aβ42                 0.83      0.74--0.91   \<48          73                    78
  **VALIDATION COHORT-COHORT 2**                                                              
  AD: *n* = 41, VaD: *n* = 21                                                                 
  tau                              0.74      0.63--0.87   \<420         89                    60
  p-tau                            0.78      0.65--0.90   \<65          72                    73
  Aβ42                             0.82      0.72--0.93   \>490         72                    88
  Aβ42/tau                         0.83      0.72--0.95   \>1.2         81                    73
  Aβ42/p-tau                       0.90      0.80--0.98   \>8.4         77                    93
  tau × p-tau/Aβ42                 0.87      0.77--0.97   \<44          81                    87

*AUC, 95% CI, cut-off value as well as sensitivity and specificity values are indicated for single biomarkers and combination of biomarkers*.

Therefore, we explored if the diagnostic accuracy may be improved by combining different biomarkers. Indeed, the combination of all three biomarkers in form of Aβ42/tau, Aβ42/p-tau, and tau × p-tau/Aβ42 revealed higher AUC values than single biomarker measurements. AUC values ranged from 0.79 to 0.90 (Table [2](#T2){ref-type="table"}). Highest diagnostic accuracy in both cohorts was detected for Aβ42/p-tau ratio: AUC: 0.84, 95% CI: 0.75--0.93, sensitivity of 81% and a specificity of 80% in cohort 1 and AUC: 0.90, 95% CI: 0.80--0.98, sensitivity of 77% and a specificity of 93% in the validation cohort (Table [2](#T2){ref-type="table"}, Supplementary Figure [1](#SM1){ref-type="supplementary-material"}). Interestingly, cut-off values for combined biomarkers were similar between both cohorts (Table [2](#T2){ref-type="table"}). For those biomarker ratios showing higher clinical accuracy we used cut-offs determined in the study cohort to test the diagnostic performance on the validation cohort. For Aβ42/p-tau, using an optimal cut off of 8.2 determined from study cohort, a sensitivity of 72% and a specificity of 95% was detected in the validation cohort. For tau × p-tau/Aβ42, using an optimal cut-off of 48 determined from study cohort, a sensitivity of 81% and a specificity of 85% was detected in validation cohort. This data indicates that parameters detected from the intra-cohort validation analysis were in range than those detected from the two cohorts individually (Table [2](#T2){ref-type="table"}).

Discussion {#s4}
==========

In patients with late-onset AD, approximately 24% of cases show a relevant vascular pathology in autopsy (Jellinger and Attems, [@B17]). Since vascular factors, such as diabetes or arteriosclerosis, belong to the risk factors of AD and a cerebral vascular pathology may further contribute to neurodegeneration in AD, both pathologies can occur to the same time, considered as mixed dementia. In these patients, an accurate classification remains problematic (de la Torre, [@B12]; Roman and Royall, [@B32]). Therefore, we excluded VaD patients showing a pathological amyloid β ratio from analysis. This was done in order to define a group of pure VaD, assigned as validation cohort, with no or minimal interference from mixed cases.

Given the clinical overlap between AD and VaD when using established diagnostic criteria, it is highly relevant to identify either imaging or biochemical biomarkers. Indeed, symptoms and pathophysiology often overlap and patients may experience similar cognitive, functional and behavioral changes (Roman and Royall, [@B32]). Previous studies often focused on the differentiation between AD and controls without neurodegeneration, but only few reports addressed the more challenging discrimination between AD and VaD patients (Andreasen et al., [@B3]; Nagga et al., [@B28]; Paraskevas et al., [@B29]; Kaerst et al., [@B20]; Skillback et al., [@B43]), most of them focusing on the classical CSF AD biomarkers. Therefore, the aim of this study was to extent the profiling of neurodegenerative marker-proteins in the CSF of AD and VaD patients because medical care plan and pharmaceutical treatments might be different for these two disease populations. In addition to classical markers in AD, such as total tau, p-tau, and Aβ42, we focused on alternative markers for neuronal degeneration for the first time, such as 14-3-3 (Sanchez-Juan et al., [@B35]; Schmitz et al., [@B39]) and NSE (Zerr et al., [@B54]), both related to Creutzfeldt-Jakob disease due to massive neuronal degeneration, as well as S100B and YKL-40, two well-known markers of astrocytosis in neurodegenerative pathologies (Rothermundt et al., [@B34]; Bonneh-Barkay et al., [@B8]; Craig-Schapiro et al., [@B9]). In the validation cohort we also included the subgroups rpAD and VE with the aim to extend our analysis to different clinically relevant subgroups related to Alzheimer\'s and vascular pathology.

Cerebrospinal fluid biomarkers in the discrimination of vascular dementia from Alzheimer\'s disease
---------------------------------------------------------------------------------------------------

The biomarker detection in CSF is a useful tool to measure any signs of neurodegeneration which are relevant in several dementia diseases. Our data indicated different CSF levels of total tau, p-tau (both elevated), and Aβ42 (decreased) in AD patients when compared to VaD cases and controls. Additionally, we found in VaD patients that CSF levels of p-tau were not significantly different from controls. These findings are in agreement with other reports (Andreasen et al., [@B1], [@B2]; Nagga et al., [@B28]; Jia et al., [@B18]; Stefani et al., [@B45]; Paraskevas et al., [@B29]; Kaerst et al., [@B19]). The presence of elevated levels of the astrocytic marker YKL-40 in AD, but not in VaD, is also in line with previous reports (Janelidze et al., [@B16]). Interestingly S100B, another astrocytic marker of neuroinflammation (Donato et al., [@B13]), was elevated in AD cases compared to controls, which coincides with other studies (Peskind et al., [@B30]). The same could be observed in other neurological diseases associated to neuroinflammatory profiles (Michetti et al., [@B26]; Berger et al., [@B5]; Rejdak et al., [@B31]; Sussmuth et al., [@B47]). Altogether our data indicate that the astrocytic response and neuroinflammatory signature reported in AD pathology can be detected in the CSF of AD patients by quantification of astrocytic markers. This suggests that YKL-40 and S100B quantification could have an application in the evaluation of a potential therapeutic intervention in AD. The comparison of AD and VaD patients revealed no significant differences in YKL-40 and S100B nor in 14-3-3 and NSE levels.

Additionally, despite the increase in 14-3-3 positive cases in both diseases (compared to controls), 14-3-3 quantification does not have a clinical use in the diagnosis of AD and VaD due to its low sensitivity, which we confirmed from previous report (Blennow et al., [@B6]). Contrary to the previously reported increased NSE levels in AD and VaD cases (Blennow et al., [@B7]), we found similar NSE levels in controls, AD and VaD cases. Some explanations for these differences would be different types of controls used in both studies. Indeed, Blennow et al. used healthy individuals, while our control cohort is composed of cases with neurological alterations, which are more prone to present some kind of neuronal damage than healthy controls (Blennow et al., [@B7]).

This indicates that neuronal/axonal degeneration is not an appropriate pathologic hallmark for the discrimination of both diseases in CSF, in agreement with the partial overlap on tau levels, another reported marker of axonal damage, between AD and VaD. Besides the poor diagnostic accuracy of tau in the discrimination of AD from VaD, the observation of higher tau levels, but not of 14-3-3 and NSE in AD compared to VaD would suggest that, a specific AD mechanism, rather than axonal damage, contributes to elevated CSF tau in AD.

The validation of total tau, p-tau, and Aβ42 in a validation cohort of patients confirmed our observations and additionally revealed that AD biomarkers were not adequate to discriminate between AD and rpAD nor between VaD and VE. A lack of differences between both AD forms suggest the absence of differential pathology at the time of diagnosis because CSF tau, p-tau, and Aβ42 reflect pathophysiological processes of the brain correlating with amyloid plaques and neurofibrillary tangles (Tapiola et al., [@B49], [@B48]). Additionally, our data indicate that tau, p-tau, and Aβ42 are not valuable markers predicting cognitive decline in clinically diagnosed AD patients.

The calculation of the diagnostic accuracy revealed sensitivity and specificity values varying between 62--89 and 60--88%, respectively for single biomarkers. These data are in agreement with Stefani et al., who suggested that Aβ42 alone showed a good discrimination between AD and VaD. The authors obtained sensitivity and specificity values of 77 and 80% (Stefani et al., [@B45]). In this regard, although study cohort could be considered more representative of the overall patient population (patients who underwent lumbar puncture for diagnostic purposes in our Clinical Dementia Center) than validation cohort (cases recruited for independent studies when AD or VaD diagnosis was suspected), overall diagnostic parameters were similar in both cohorts.

Before this study, there were only a few studies using the combination of different neurodegenerative markers to distinguish between AD and VaD (Andreasen et al., [@B3]; Paraskevas et al., [@B29]). Our results are in line with two other studies which suggested either the ratio of Aβ42/p-tau CSF levels or the combination of total tau, p-tau, and Aβ42 for a differentiation between AD and VaD patients. Both studies achieved discrimination with a sensitivity and specificity of 85% (Paraskevas et al., [@B29]). However, our results indicate that neither measurement of CSF tau, p-tau, or Aβ42 alone, nor the combination of these biomarkers can discriminate entirely between AD and VaD cases.

Conclusions {#s5}
===========

In conclusion, our present study suggests that the combination of AD biomarkers especially Aβ42/p-tau and tau × p-tau/Aβ42 may be helpful for the discrimination of AD from VaD. Additional markers, such as YKL40, S100B, NSE, and 14-3-3 failed in distinguishing between diseases. For a further improvement of diagnostic accuracy, the identification of additional CSF biomarkers is required.
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AD

:   Alzheimer\'s disease

Aβ42

:   amyloid beta 1--42 peptide

CSF

:   cerebrospinal fluid

ELISA

:   enzyme-linked immunosorbent assay

p-tau

:   phosphorylated tau

VE

:   vascular encephalopathy

VaD

:   vascular dementia.
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